| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2024-074 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司（以下简称"公司"）于近日收到持股5%以上股 东朱志宏先生的通知，获悉朱志宏先生将所持有的公司部分股份进行了质押，具 体情况如下： 一、股东股份质押的基本情况 | 股东 | 是否为第一 大股东及一 | | 本次质押股 | 占其所 持股份 | 占公司 总股本 | 是否为 | 是否为 补充质 | 质押 | 质押 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | 份数量（股） | | | 限售股 | | 开始日期 | 到期日 | | 用途 | | | 致行动人 | | | 比例 | 比例 | | 押 | | | | | | 朱志宏 | | 是 | 5,200,000 | 3.16% | 1.06% | 否 | 否 | 2024-11-6 | 办理解 除质押 | ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2024-073 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 注册分类：中药 1.1 类 剂型：贴膏剂 湖南九典制药股份有限公司 功能主治：温经散寒，活血止痛 关于撤回药品注册申请的进展公告 受理号：CXZS2300028 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的《药品注册申请终止通知书》，同意公司撤回椒七麝凝胶贴膏 的药品注册申请报告，现将相关信息披露如下： 一、药品的基本信息 药品名称：椒七麝凝胶贴膏 审查结论：根据《药品注册管理办法》第八十九条以及申请人的撤回申请， 同意本品注册申请撤回，终止注册程序。 二、同类药品的情况 椒七麝凝胶贴膏是公司基于临床经验方开发的局部经皮给药制剂，具有温经 散寒、活血止痛的作用，用于寒凝血瘀所致的痹病，症见关节疼痛、压痛、局部 畏寒、得温痛减、关节活动不利、僵硬重滞；骨性关节炎等见上述证候者。上述 症状常 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark within the next six months [16]. Core Insights - The company reported a revenue of 2.15 billion with a year-on-year growth of 13.4% and a net profit attributable to the parent company of 450 million, reflecting a significant year-on-year increase of 45.1% for the first three quarters of 2024 [1]. - The company has a robust pipeline of over 20 external preparations under research, with key products including Lidocaine gel patches and Loxoprofen sodium patches, indicating strong long-term growth potential [3]. - The company has effectively controlled costs, with a notable decrease in sales expense ratio by 6.7 percentage points year-on-year, demonstrating improved management efficiency [2]. Financial Performance - For the first three quarters of 2024, the gross profit margin was 73.8%, a decrease of 4.2 percentage points year-on-year, while the sales expense ratio was 39.9%, down 6.7 percentage points year-on-year [2]. - The company forecasts net profits of 520 million, 680 million, and 890 million for the years 2024, 2025, and 2026 respectively, maintaining previous estimates [5]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 1.06, 1.38, and 1.82 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 22.4, 17.1, and 13.0 [7][14].

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2024-072 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 | 股东名称 | 减持原因 | 股份来源 | 减持数量及比例 | 减持方式 | 减持期间 | 减持价格 | | --- | --- | --- | --- | --- | --- | --- | | 段立新 | | 首次公开发行 | | | 26 日-2025 | | | | | 前已发行的股 | 不超过 | | 2024年11月 | 不低于公 | | | 个人资金 | 份及资本公积 | 14,772,180 股， | 集中竞价、 | | 司首次公 | | | 需求 | 金转增股份、股 | 占本公司总股本 | 大宗交易 | | 开发行价 | | | | | | | 年 2 月 25 日 | | | | | 权激励计划授 | 的 3%。 | | | 格 | | | | 予的股份 | | | | | 注：若计划减持期间公司有送股、资本公积转增股本等变动事项，应对上述 减持数量做相应调整。 关于股东减持 ...

九典制药：股东计划减持公司股份不超过3% 财联社11月4日电，九典制药公告，公司持股5%以上股东 段立新计划在本公告披露日起15个交易日后的3个月内，以集中竞价交易或大宗交易方式减持公司股份 不超过14,772,180股，占公司总股本比例的3%。 查看公告原文 ...

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2024-071 | 湖南九典制药股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南九典制药股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日、2024 年 5 月 15 日分别召开的第四届董事会第四次会议及 2023 年度股东大会审议通过 了《关于为全资子公司申请银行授信提供担保的议案》，同意公司为全资子公司 湖南九典宏阳制药有限公司（以下简称"九典宏阳"）向银行申请总额不超过 7.9 亿元的综合授信额度提供连带责任保证。 具体内容详见公司于 2024 年 4 月 25 日、2024 年 5 月 15 日在巨潮资讯网上 披露的相关公告。 二、担保进展情况 近日，公司全资子公司九典宏阳因生产经营需要，向上海浦东发展银行长沙 支行（以下简称"浦发银行"）申请授信。公司与浦发银行签订了《最高额保证 合同》，为全资子 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][3]. Core Views - The company's core product, Loxoprofen Sodium Gel Patch, continues to see significant growth, particularly in the outpatient market, which is developing rapidly. The report expresses optimism about the company's future development [3]. - The company's profit performance remains strong, with a notable increase in net profit and continuous optimization of expense ratios, leading to a steady improvement in profitability [1][3]. Financial Performance Summary - For the first three quarters of 2024, the company achieved operating revenue of 2.146 billion yuan, a year-on-year increase of 13.36%. The net profit attributable to the parent company was 450 million yuan, up 45.08% year-on-year, while the net profit excluding non-recurring items was 418 million yuan, reflecting a growth of 44.82% [1]. - In Q3 2024, the company reported operating revenue of 780 million yuan, a year-on-year increase of 15.47%, and a net profit attributable to the parent company of 47.37%, indicating sustained high growth in profits [1]. - The gross profit margin for the first three quarters was 73.76%, a decrease of 4.23 percentage points year-on-year, while the net profit margin increased by 4.58 percentage points to 20.96% [1]. - The company’s sales expense ratio decreased by 6.73 percentage points to 39.85%, attributed to multiple factors including the gradual stabilization of prices in the hospital market and the ongoing transformation of marketing models [1]. Future Projections - The report projects revenues for 2024, 2025, and 2026 to be 3.106 billion yuan, 3.615 billion yuan, and 4.243 billion yuan, respectively, with year-on-year growth rates of 15%, 16%, and 17% [3]. - The net profit attributable to the parent company is expected to reach 515 million yuan, 682 million yuan, and 906 million yuan for the years 2024, 2025, and 2026, respectively, with growth rates of 40%, 32%, and 33% [3].

Group 1: Product Performance and Market Position - The current status of the Loxoprofen Sodium Gel Patch in local procurement shows that it has been executed in 20 administrative regions, with provincial procurement completed in all areas except Beijing, Shanghai, and Shandong [1] - The company expects stable growth for the Loxoprofen Sodium Gel Patch over the next 2-3 years, with minimal impact on performance due to competition [2] - The market for external patches was approximately ¥203.64 billion in 2023, showing a growth rate of around 10% compared to ¥184 billion in 2022 [3] Group 2: Financial Outlook - The company anticipates a revenue growth of 10-20% for the year 2024, with a non-net profit growth of 30-40% [2] - The financial forecasts are subject to market conditions and other uncertainties, emphasizing the need for investors to remain aware of risks [2] Group 3: Production Capacity and Planning - Current production capacity meets existing demand, with plans for additional production lines to accommodate future sales needs [2] - The company has reserved workshop space for potential capacity expansion based on operational development needs [2] Group 4: Competitive Analysis - The Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch differ in active ingredients and mechanisms, with Loxoprofen Sodium being more effective for a broader range of conditions [3] - As of September 30, 2024, the Ketoprofen Gel Patch has been developed in over 800 secondary and tertiary hospitals, and more than 800 primary hospitals, totaling nearly 2,000 development endpoints [3] Group 5: Market Trends - The market share of chemical drug patches is steadily increasing, with a compound annual growth rate of approximately 9.67% in hospitals over the past three years, compared to 0.56% for traditional Chinese medicine patches [3] - The company has successfully developed the Loxoprofen Sodium Gel Patch in 450 chain stores, covering nearly 120,000 outlets as of September 2024 [3]

一、可转换公司债券基本情况 经中国证券监督管理委员会证监许可〔2023〕526 号文同意注册，公司于 2023 年 9 月 15 日向不特定对象发行了 360.00 万张可转换公司债券（以下简称"可转 债"），每张面值 100 元，发行总额为 36,000.00 万元。 经深圳证券交易所（以下简称"深交所"）同意，公司可转债于 2023 年 10 月 13 日起在深交所挂牌交易，债券简称：九典转 02，债券代码：123223。 根据《深圳证券交易所创业板股票上市规则》的规定和《湖南九典制药股份 有限公司创业板向不特定对象发行可转换公司债券募集说明书》（以下简称"《募 集说明书》"）的约定，公司可转债的转股期限自 2024 年 3 月 21 日起至 2029 年 9 月 14 日止。 二、可转换公司债券有条件赎回条款与触发情况 （一）有条件赎回条款 西部证券股份有限公司 关于湖南九典制药股份有限公司 不提前赎回九典转 02 的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南九 典制药股份有限公司（以下简称"九典制药"、"公司"）向不特定对象发行可转 换公司债券的保荐人，根据《证券发行上 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2024-069 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖南九典制药股份有限公司（以下简称"公司"）第四届董事会第八次会议 于 2024 年 11 月 1 日以通讯方式召开，经全体董事一致同意豁免会议通知时间要 求，会议通知已于 2024 年 11 月 1 日以邮件方式送达。本次会议应出席的董事 7 人，实际出席的董事 7 人，全体监事、高级管理人员及保荐代表人列席了会议， 本次会议由董事长朱志宏先生主持。本次会议的召开符合有关法律、法规和《公 司章程》的规定，形成的决议合法有效。 二、董事会会议审议情况 审议通过了《关于不提前赎回九典转 02 的议案》。 经审议，董事会认为：2024 年 10 月 14 日至 2024 年 11 月 1 日期间，公司 股票已满足在任何连续30个交易日中至少15个交易 ...